44 related articles for article (PubMed ID: 19789416)
1. Blood eicosapentaenoic acid and docosahexaenoic acid as predictors of all-cause mortality in patients with acute myocardial infarction--data from Infarction Prognosis Study (IPS) Registry.
Lee SH; Shin MJ; Kim JS; Ko YG; Kang SM; Choi D; Jang Y; Chung N; Shim WH; Cho SY; Manabe I; Ha JW
Circ J; 2009 Dec; 73(12):2250-7. PubMed ID: 19789416
[TBL] [Abstract][Full Text] [Related]
2. Sex Differences in Omega-3 and -6 Fatty Acids and Health Status Among Young Adults With Acute Myocardial Infarction: Results From the VIRGO Study.
Lu Y; Ding Q; Xu X; Spatz ES; Dreyer RP; D'Onofrio G; Caulfield M; Nasir K; Spertus JA; Krumholz HM
J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29848494
[TBL] [Abstract][Full Text] [Related]
3. Relevance of target-organ lesions as predictors of mortality in patients with diabetes mellitus.
Bianco HT; Izar MC; Fonseca HA; Póvoa RM; Saraiva JF; Forti A; Jardim PC; Introcaso L; Yugar-Toledo J; Xavier HT; Faludi AA; Fonseca FA
Arq Bras Cardiol; 2014 Oct; 103(4):272-81. PubMed ID: 25098376
[TBL] [Abstract][Full Text] [Related]
4. Circulating Docosahexaenoic Acid and Risk of All-Cause and Cause-Specific Mortality.
O'Keefe EL; O'Keefe JH; Tintle NL; Westra J; Albuisson L; Harris WS
Mayo Clin Proc; 2024 Apr; 99(4):534-541. PubMed ID: 38506781
[TBL] [Abstract][Full Text] [Related]
5. Factors Associated With Mortality During the First Year Post Infarction: Survival Analysis of Patients With Acute Myocardial Infarction in Colombia.
Bermon A; Licht-Ardila M; Manrique-Hernández F; Hurtado-Ortiz A; Cañon D; Molina Castaño CF
Cureus; 2024 Apr; 16(4):e58118. PubMed ID: 38738138
[TBL] [Abstract][Full Text] [Related]
6. Negative relationship between eicosapentaenoic acid and inflammatory biomarkers in patients with acute myocardial infarction.
Masson D; Leleu D; Farnier M; Chagué F; Rampon C; Bichat F; Demeule C; Maza M; Pais de Barros JP; Cottin Y; Zeller M
Cardiovasc Res; 2024 Mar; 120(2):111-113. PubMed ID: 38193579
[No Abstract] [Full Text] [Related]
7. Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.
Bays HE; Ballantyne CM; Braeckman RA; Stirtan WG; Doyle RT; Philip S; Soni PN; Juliano RA
Metab Syndr Relat Disord; 2015 Aug; 13(6):239-47. PubMed ID: 25893544
[TBL] [Abstract][Full Text] [Related]
8. Higher ratio of plasma omega-6/omega-3 fatty acids is associated with greater risk of all-cause, cancer, and cardiovascular mortality: A population-based cohort study in UK Biobank.
Zhang Y; Sun Y; Yu Q; Song S; Brenna JT; Shen Y; Ye K
Elife; 2024 Apr; 12():. PubMed ID: 38578269
[TBL] [Abstract][Full Text] [Related]
9. The Emerging Role of Icosapent Ethyl in Patients with Cardiovascular Disease: Mechanistic Insights and Future Applications.
Gupta A; Alkhalil M
J Clin Med; 2023 May; 12(11):. PubMed ID: 37297952
[TBL] [Abstract][Full Text] [Related]
10. A Fishy Topic: VITAL, REDUCE-IT, STRENGTH, and Beyond: Putting Omega-3 Fatty Acids into Practice in 2021.
Iqbal T; Miller M
Curr Cardiol Rep; 2021 Jul; 23(8):111. PubMed ID: 34247311
[TBL] [Abstract][Full Text] [Related]
11. An omega-3 fatty acid plasma index ≥4% prevents progression of coronary artery plaque in patients with coronary artery disease on statin treatment.
Alfaddagh A; Elajami TK; Saleh M; Mohebali D; Bistrian BR; Welty FK
Atherosclerosis; 2019 Jun; 285():153-162. PubMed ID: 31055222
[TBL] [Abstract][Full Text] [Related]
12. Seafood Long-Chain n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: A Science Advisory From the American Heart Association.
Rimm EB; Appel LJ; Chiuve SE; Djoussé L; Engler MB; Kris-Etherton PM; Mozaffarian D; Siscovick DS; Lichtenstein AH;
Circulation; 2018 Jul; 138(1):e35-e47. PubMed ID: 29773586
[TBL] [Abstract][Full Text] [Related]
13. The ratio of serum n-3 to n-6 polyunsaturated fatty acids is associated with diabetes mellitus in patients with prior myocardial infarction: a multicenter cross-sectional study.
Takahashi M; Ando J; Shimada K; Nishizaki Y; Tani S; Ogawa T; Yamamoto M; Nagao K; Hirayama A; Yoshimura M; Daida H; Nagai R; Komuro I
BMC Cardiovasc Disord; 2017 Jan; 17(1):41. PubMed ID: 28125968
[TBL] [Abstract][Full Text] [Related]
14. The vital prognosis of elderly adults living in a group home in their mid-eighties.
Todoroki K; Ikeya Y; Fukui S; Tanaka C; Sekine K; Imazeki R; Shizuma T; Fukuyama N; Mori H
J Physiol Sci; 2017 Sep; 67(5):561-568. PubMed ID: 27655021
[TBL] [Abstract][Full Text] [Related]
15. Association between the docosahexaenoic acid to arachidonic acid ratio and acute coronary syndrome: a multicenter observational study.
Nishizaki Y; Shimada K; Tani S; Ogawa T; Ando J; Takahashi M; Yamamoto M; Shinozaki T; Miyazaki T; Miyauchi K; Nagao K; Hirayama A; Yoshimura M; Komuro I; Nagai R; Daida H
BMC Cardiovasc Disord; 2016 Jul; 16(1):143. PubMed ID: 27387342
[TBL] [Abstract][Full Text] [Related]
16. N-3 long-chain polyunsaturated fatty acids and risk of all-cause mortality among general populations: a meta-analysis.
Chen GC; Yang J; Eggersdorfer M; Zhang W; Qin LQ
Sci Rep; 2016 Jun; 6():28165. PubMed ID: 27306836
[TBL] [Abstract][Full Text] [Related]
17. Which has the stronger impact on coronary artery disease, eicosapentaenoic acid or docosahexaenoic acid?
Iwamatsu K; Abe S; Nishida H; Kageyama M; Nasuno T; Sakuma M; Toyoda S; Inoue T
Hypertens Res; 2016 Apr; 39(4):272-5. PubMed ID: 26739870
[TBL] [Abstract][Full Text] [Related]
18. Polyunsaturated fatty acid intake and risk of cardiovascular mortality in a low fish-consuming population: a prospective cohort analysis.
Owen AJ; Magliano DJ; O'Dea K; Barr EL; Shaw JE
Eur J Nutr; 2016 Jun; 55(4):1605-13. PubMed ID: 26201872
[TBL] [Abstract][Full Text] [Related]
19. Eicosapentaenoic acid/arachidonic acid ratio and smoking status in elderly patients with type 2 diabetes mellitus.
Okada K; Kotani K; Yagyu H; Ishibashi S
Diabetol Metab Syndr; 2014; 6(1):85. PubMed ID: 25143787
[TBL] [Abstract][Full Text] [Related]
20. Baseline plasma fatty acids profile and incident cardiovascular events in the SU.FOL.OM3 trial: the evidence revisited.
Fezeu LK; Laporte F; Kesse-Guyot E; Andreeva VA; Blacher J; Hercberg S; Galan P
PLoS One; 2014; 9(4):e92548. PubMed ID: 24710321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
